Week in Review: September 23–27

Antibiotic cycling makes a comeback in the lab; how life scientists can learn from astronauts; napping to conquer fears; deconstructing the cancer R&D crisis

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

FLICKR, ROBSON#Switching up the antibiotics used to treat bacterial infections is by no means a revolutionary concept. “Cycling—or rotating antibiotics—has been a hope for a number of years,” Rush University’s Robert Weinstein told The Scientist. The hope is to effectively “confuse the bacteria by changing the class of antibiotics you use,” he added.

A pair of researchers from Technical University of Denmark this week proposed a new approach, called collateral sensitivity cycling, which they said could be used to both better treat illness and to spurn the emergence of drug resistance. Lejla Imamovic and Morten Sommer analyzed wild-type Escherichia coli and strains evolved in the laboratory to be resistant to 23 commonly used antibiotics, then treated the bacteria with pairs of drugs in a cyclical fashion. The research revealed sets of antibiotics that successfully killed the E. coli colonies without allowing the bacteria to evolve resistance.

The study “is an in-depth analysis of resistance linkages and susceptibilities,” said Weinstein, who was not involved in the work. “It’s an important topic because . . . development of antimicrobial drugs ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo